Introduction
============

Cholangiocarcinoma (CCA) originates in the epithelium of hepatic biliary trees and is the second most common fatal primary hepatobiliary malignant carcinoma.[@b1-ott-12-1905] According to recent epidemiological data, the incidence and mortality of CCA in the world has been increasing rapidly over the past decades.[@b2-ott-12-1905],[@b3-ott-12-1905] However, due to the lack of a specific clinical presentation and effective diagnostic systems for CCA, most of CCA patients are diagnosed at advanced stages.[@b2-ott-12-1905],[@b4-ott-12-1905] Additionally, due to tumor resistance to traditional chemotherapy and radiotherapy, surgery is currently the most effective treatment for CCA.[@b3-ott-12-1905] As a result, the prognosis of patients with CCA is extremely poor, with a high rate of recurrence, and a 5-year survival rate of only 5%.[@b5-ott-12-1905],[@b6-ott-12-1905] For these reasons, identifying new therapeutic targets and novel biomarkers associated with CCA diagnosis and prognosis is very important to improve outcomes for those with this disease.

lncRNAs are RNA molecules transcribed without functional open reading frames and are \>200 nucleotides in length.[@b7-ott-12-1905] They function in various biological processes mostly by binding with miRNAs as sponges or interacting with proteins, including those active in cell proliferation, migration, invasion, and apoptosis.[@b8-ott-12-1905] Recently, numerous studies indicated that aberrant expression of lncRNAs was involved in tumorigenesis and cancer progression, including CCA.[@b7-ott-12-1905]--[@b10-ott-12-1905] Emerging evidence also demonstrated that some lncRNAs are associated with the diagnosis and prognosis of CAA.[@b8-ott-12-1905],[@b11-ott-12-1905],[@b12-ott-12-1905]

However, due to limitations related to small sample sizes and various experimental protocols, a single study on these topics may be inaccurate and are therefore insufficiently powered to inform solid conclusions. Thus, the aim of the present study was to systematically analyze all studies of CAA to assess the potential clinical value of lncRNAs in CAA. Here, we identify the relationship between lncRNAs expression and three different clinical outcomes (clinicopathological characteristics, diagnosis, and prognosis).

Methods
=======

Search strategy
---------------

Two of the authors (KD and JQ) independently searched several databases, including PubMed, Embase, the Cochrane Library, China National Knowledge Internet (CNKI), Wanfang and Weipu database, for studies on lncRNAs and CCA. The literature was searched up to September 13, 2018. The search terms were as follows: Search (((((((((((((((((((((((((((((Non-coding RNA, Long\[Title/Abstract\]) OR lncRNA\[Title/Abstract\]) OR Long ncRNA\[Title/Abstract\]) OR ncRNA, Long\[Title/Abstract\]) OR RNA, Long Non-Translated\[Title/Abstract\]) OR Long Non-Translated RNA\[Title/Abstract\]) OR Non-Translated RNA, Long\[Title/Abstract\]) OR RNA, Long Non Translated\[Title/Abstract\]) OR Long Non-Coding RNA\[Title/Abstract\]) OR Long Non Coding RNA\[Title/Abstract\]) OR Non-Coding RNA, Long\[Title/Abstract\]) OR RNA, Long Non-Coding\[Title/Abstract\]) OR Long Non-Protein-Coding RNA\[Title/Abstract\]) OR Long Non Protein Coding RNA\[Title/Abstract\]) OR Non-Protein-Coding RNA, Long\[Title/Abstract\]) OR RNA, Long Non-Protein-Coding\[Title/Abstract\]) OR Long Noncoding RNA\[Title/Abstract\]) OR RNA, Long Untranslated\[Title/Abstract\]) OR Long Untranslated RNA\[Title/Abstract\]) OR Untranslated RNA, Long\[Title/Abstract\]) OR Long ncRNAs\[Title/Abstract\]) OR ncRNAs, Long\[Title/Abstract\]) OR Long Intergenic Non-Protein Coding RNA\[Title/Abstract\]) OR Long Intergenic Non Protein Coding RNA\[Title/Abstract\]) OR LincRNAs\[Title/Abstract\]) OR LINC RNA\[Title/Abstract\])) OR "RNA, Long Noncoding"\[Mesh\])) AND (((((((((((((((Cholangiocarcinomas\[Title/Abstract\]) OR Cholangiocellular Carcinoma\[Title/Abstract\]) OR Carcinoma, Cholangiocellular\[Title/Abstract\]) OR Carcinomas, Cholangiocellular\[Title/Abstract\]) OR Cholangiocellular Carcinomas\[Title/Abstract\]) OR Extrahepatic Cholangiocarcinoma\[Title/Abstract\]) OR Cholangiocarcinoma, Extrahepatic\[Title/Abstract\]) OR Chol-angiocarcinomas, Extrahepatic\[Title/Abstract\]) OR Extrahepatic Cholangiocarcinomas\[Title/Abstract\]) OR Intrahepatic Cholangiocarcinoma\[Title/Abstract\]) OR Cholangiocarcinoma, Intrahepatic\[Title/Abstract\]) OR Cholangiocarcinomas, Intrahepatic\[Title/Abstract\]) OR Intrahepatic Cholangiocarcinomas\[Title/Abstract\])) OR "Cholangiocarcinoma"\[Mesh\]).

### Inclusion and exclusion criteria

The inclusion criteria were as follows: 1) patients diagnosed with CCA by histopathology; 2) the expression level of lncRNAs divided into high and low, and the correlation between lncRNAs expression and clinicopathological features were detailed; 3) the relationship between lncRNA expression and survival outcome, hazard risk (HR), 95% CI, or *P*-value, and Kaplan--Meier curves were outlined; 4) the expression of lncRNAs was detected in the tissue or serum, and sufficient data on sensitivity, specificity, and sample size were presented.

The exclusion criteria were as follows: 1) non-human studies; 2) letters, case reports, commentaries, conference abstracts, or review articles; 3) articles unrelated to lncRNA and CCA; 4) insufficient data for extraction; 5) HRs calculated using multiple lncRNAs; 6) studies focused on genetic polymorphisms or modification of lncRNAs.

Data extraction and quality assessment
--------------------------------------

Two independent authors (KD and JQ) extracted the information from the included literature using a predefined template based on the reporting checklists of PRISMA:[@b13-ott-12-1905] 1) the first author's last name and publication year; 2) the type of lncRNA, study population, region, sample number, follow-up time (months), and detection methods; 3) clinicopathological features: age, gender, tumor size, histological grade, tumor stage, lymph node metastasis, distant metastasis, carbohydrate antigen 199, alpha-fetoprotein (AFP), and hepatitis B virus (HBV) infection; 4) HRs, 95 % CI, and *P*-value for survival analysis. If HRs were directly available, we collected these from the original studies, otherwise these data were indirectly extracted from Kaplan--Meier curves according to the method of Tierney et al[@b14-ott-12-1905] or we asked the authors for these data; and 5) diagnostic data were included: sensitivity, specificity, and area under curve (AUC).

We assessed the quality of all the included diagnostic studies according to the Quality Assessment of Diagnostic Accuracy Studies-2[@b15-ott-12-1905] criteria and used the Newcastle-Ottawa Scale[@b16-ott-12-1905] to assess the quality of the selected prognostic studies (scores \>5 was regarded as high quality).

Statistical analysis
--------------------

Heterogeneity among articles was assessed with Higgin's *I*[@b2-ott-12-1905] statistic. *I*[@b2-ott-12-1905]\>50% indicated statistically significant heterogeneity. A fixed-effects or random-effects model was applied to evaluate the relationship between lncRNAs expression and survival outcomes. A fixed-effects model was used when heterogeneity among studies was not obvious. Otherwise, a random-effects model was used.[@b17-ott-12-1905],[@b18-ott-12-1905] A different effect size was selected for each meta-analysis: 1) that of clinicopatho-logical features analyzed OR and associated 95% CI. 2) In the diagnostic meta-analysis, sensitivity, specificity, and AUC were used. 3) The prognostic meta-analysis employed HR and associated 95% CI for each study to estimate the survival outcomes associated with the expression of lncRNA. HR \>1 was regarded as the worse survival for the group with elevated lncRNA expression.[@b18-ott-12-1905] Stata 14.0 software (StataCorp LP, College Station, TX, USA) was used to analyze study data and construct the forest plot. *P*\<0.05 was considered to be statistically significant.

Results
=======

Study identification and characteristics
----------------------------------------

As shown in the search flowchart ([Figure 1](#f1-ott-12-1905){ref-type="fig"}), 88 articles in total were retrieved from PubMed, Embase, Cochrane, and three Chinese databases (China Knowledge Resource Integrated, Wanfang, and Weipu databases). Further, 20 articles were excluded as duplicates. After reviewing the remaining titles and abstracts carefully, 36 studies were removed, including 5 non-human studies; 1 study not on CCA; 14 studies unrelated to clinicopathological features, diagnosis, or prognosis; 6 studies without lncRNAs; 8 reviews or meeting reviews; and 4 more duplicate articles. Finally, 24 studies were deemed eligible for meta-analysis upon further review of the full-text article, including 16 discussing on clinicopathological characteristics, 2 on diagnosis, and 16 on prognosis.

Clinicopathological characteristics
-----------------------------------

Herein, 14 lncRNAs were described in 13 included studies on clinicopathological characteristics. As shown in the [Table 1](#t1-ott-12-1905){ref-type="table"}, except EMP1-008[@b19-ott-12-1905] and ATF3-008,[@b19-ott-12-1905] almost all lncRNAs were upregulated in CCA, including H19,[@b20-ott-12-1905],[@b21-ott-12-1905] CPS1-IT1,[@b22-ott-12-1905] RCOR3-013,[@b19-ott-12-1905] TMEM63A-005,[@b19-ott-12-1905] CCAT1,[@b23-ott-12-1905],[@b24-ott-12-1905] PANDAR,[@b8-ott-12-1905] AFAP1-AS1,[@b11-ott-12-1905] Linc01296,[@b6-ott-12-1905] MALAT1,[@b12-ott-12-1905] UCA1,[@b25-ott-12-1905] Sox2ot,[@b26-ott-12-1905] CRNDE,[@b27-ott-12-1905] CCAT2,[@b28-ott-12-1905],[@b29-ott-12-1905] and HOTAIR.[@b30-ott-12-1905] All studies indicated that lncRNAs were not significantly associated with patient age, gender, and HBV infection status. Few studies demonstrated that the expression levels of lncRNAs were associated with AFP, except H19.[@b20-ott-12-1905] Only one study indicated that CPS1-IT1 expression was significantly related to carcinoembryonic antigen (CEA),[@b22-ott-12-1905] and seven studies reported that six lncRNAs were significantly correlated with tumor size, including H19,[@b20-ott-12-1905],[@b21-ott-12-1905] AFAP1-AS1,[@b11-ott-12-1905] Linc01296,[@b6-ott-12-1905] MALAT1,[@b12-ott-12-1905] CRNDE,[@b25-ott-12-1905] and HOTAIR.[@b30-ott-12-1905]

Only four studies found that lncRNAs were significantly associated with histological grade of CCA, while 13 studies claimed that lncRNAs were significantly correlated with tumor grade of CCA. Interestingly, [Table 1](#t1-ott-12-1905){ref-type="table"} shows that AFAP1-AS1 and CCAT2 expressions were significantly related to vascular invasion.[@b11-ott-12-1905],[@b28-ott-12-1905] Additionally, ten studies demonstrated that lncRNAs were significantly associated with lymph node metastasis, while three studies reported that lncRNAs were significantly correlated with distant metastasis. [Table 1](#t1-ott-12-1905){ref-type="table"} also revealed that H19, CCAT1, and CCAT2 were all detected in two articles. Therefore, we combined these two studies with a total of six groups by constructing two-by-two tables. However, H19 could not be further analyzed due to insufficient data. Based on our meta-analysis of these articles describing CCAT1, the relationship between upregulation of CCAT1 and tumor stage (I + II vs III + IV) was indeed significant (OR, 4.99; 95% CI 2.77--8.99; *P*\<0.001). Furthermore, overexpression CCAT1 was significantly correlated with the lymph node metastasis in CCA (OR, 4.75; 95% CI 2.65--8.52; *P*\<0.001) ([Figure 2](#f2-ott-12-1905){ref-type="fig"}). Similarly, the result about CCAT2 also indicated that upregulation of CCAT2 was obviously associated with tumor stage in CCA (OR, 5.29; 95% CI 2.64--10.58; *P*=0.001) ([Figure 3](#f3-ott-12-1905){ref-type="fig"}). However, dysfunction of CCAT2 was not related with age, gender, and tumor size (*P*\>0.05).

Diagnosis
---------

Only two studies about three lncRNAs were included in this topical analysis. All these lncRNAs were upregulated in different detected samples using real-time quantitative PCR (RT-qPCR). Jiang et al indicated that CCAT1 acted as a potential biomarker for the diagnosis of CCA with relative high sensitivity (81.80%) and specificity (74.50%).[@b23-ott-12-1905] Furthermore, Ge et al detected ENST00000517758.1 and ENST00000588480.1 in bile samples and found they were both potential biomarkers for the diagnosis of CCA.[@b31-ott-12-1905] The main characteristics of these two studies are presented in [Table 2](#t2-ott-12-1905){ref-type="table"}.

Prognosis
---------

Briefly, 16 different lncRNAs were described in the 16 included studies on prognosis. The characteristics of these eligible studies are presented in [Table 3](#t3-ott-12-1905){ref-type="table"}. The lncRNA expression of all samples was detected from tissues by RT-qPCR. This analysis included 585 patients with high expression and 522 patients with low expression in total. Interestingly, all of these lncRNAs were overexpressed in CCA, with elevated expression levels associated with poor prognosis, including CPS1-IT1,[@b22-ott-12-1905] CCAT1,[@b23-ott-12-1905] TUG1,[@b32-ott-12-1905] PANDAR,[@b8-ott-12-1905] AFAP1-AS1,[@b11-ott-12-1905] LINC01296,[@b6-ott-12-1905] MALAT1,[@b12-ott-12-1905] UCA1,[@b25-ott-12-1905] Sox2ot,[@b26-ott-12-1905] CRNDE,[@b27-ott-12-1905] H19,[@b21-ott-12-1905] SPRY4-IT1,[@b33-ott-12-1905] ENST00000588480.1,[@b31-ott-12-1905] ENST00000517758.1,[@b31-ott-12-1905] CCAT2,[@b28-ott-12-1905],[@b34-ott-12-1905] and HOTAIR[@b30-ott-12-1905] ([Figure 4](#f4-ott-12-1905){ref-type="fig"}). Among them, Sox2ot[@b26-ott-12-1905] had the highest HR of 2.936, while CRNDE[@b27-ott-12-1905] displayed the lowest HR with 1.309.

Among these 16 lncRNAs, the CCAT family was investigated in more than one study. Thus, we further analyzed the relationship between the expression of CCAT gene family and overall survival (OS; [Figure 5](#f5-ott-12-1905){ref-type="fig"}). A fixed-effects model was used due to the lack of significant heterogeneity in the CCAT family (*I*[@b2-ott-12-1905]=0.0%, *P*=0.867). As a result, high CCAT family expression predicted short OS (HR, 2.09; 95% CI 1.17--3.00; *P*\<0.001). By further subgroup analysis, overexpression of CCAT2 was obviously associated with poor OS (HR, 2.00; 95% CI 0.96--3.03; *P*\<0.001). Publication bias could not be assessed because of the small size of our study.

Discussion
==========

CCA is still a deadly threat to human health due to its early invasion and metastatic characteristics and poor prognosis. According to relevant reports, the global incidence of CCA has clearly increased during the past decades, especially in Asia.[@b3-ott-12-1905],[@b35-ott-12-1905] However, current therapeutics for CAA are unsatisfactory and so novel biomarkers to diagnose CAA and predict its prognosis are urgently needed. Recently, there has been emerging evidence showing that some lncRNAs play an important role in the tumorigenesis and progression of CAA. In order to codify some of these novel biomarkers for CCA, we conducted this systematic review and meta-analysis. As a result, this meta-analysis is the first to systematically analyze the association between lncRNA expression and their clinical value in CCA.

In terms of association with clinicopathological features, H19,[@b20-ott-12-1905],[@b21-ott-12-1905] CPS1-IT1,[@b22-ott-12-1905] RCOR3-013,[@b19-ott-12-1905] TMEM63A-005,[@b19-ott-12-1905] CCAT1,[@b23-ott-12-1905],[@b24-ott-12-1905] PANDAR,[@b8-ott-12-1905] AFAP1-AS1,[@b11-ott-12-1905] Linc01296,[@b6-ott-12-1905] MALAT1,[@b12-ott-12-1905] UCA1,[@b25-ott-12-1905] Sox2ot,[@b26-ott-12-1905] CRNDE,[@b27-ott-12-1905] CCAT2,[@b28-ott-12-1905],[@b34-ott-12-1905] and HOTAIR[@b30-ott-12-1905] were overexpressed in CCA, while EMP1-008[@b19-ott-12-1905] and ATF3-008[@b19-ott-12-1905] were downregulated. All lncRNAs were not significantly associated with patient age, gender, and HBV infection.

It is well-known that AFP and CEA play an important role in the diagnosis of CCA.[@b36-ott-12-1905] However, studies did not indicate that dysregulation of lncRNAs was significantly related to AFP and CEA. Only two studies indicated that H19 expression was obviously associated with AFP,[@b20-ott-12-1905] and CPS1-IT1 expression was significantly related to CEA.[@b22-ott-12-1905] The reason for association of H19 with AFP is that the *Afp* and *H19* genes are regulated by *Afr1*, which was first identified in 1977 using persistent AFP serum levels.[@b37-ott-12-1905],[@b38-ott-12-1905] There is no direct evidence for the relationship between CPS1-IT1 and CEA.

Similarly, we found that six lncRNAs were significantly correlated with tumor size, including H19,[@b20-ott-12-1905],[@b21-ott-12-1905] AFAP1-AS1,[@b11-ott-12-1905] Linc01296,[@b6-ott-12-1905] MALAT1,[@b12-ott-12-1905] CRNDE,[@b25-ott-12-1905] CCAT2,[@b28-ott-12-1905],[@b34-ott-12-1905] and HOTAIR.[@b30-ott-12-1905] However, the correlation remained uncertain due to the different evaluation criteria for tumor size. For example, in the study about association between H19 expression and tumor size, Wang et al[@b20-ott-12-1905] selected 5 cm as the criterion for tumor size, while Xu et al[@b21-ott-12-1905] used 3 cm as the threshold of tumor size. The reason why some lncRNAs were significantly correlated with tumor size is still uncertain. Moreover, most lncRNAs were significantly correlated with tumor grade of CCA, which meant these lncRNAs were correlated with the progression of CCA.

Ten studies demonstrated that lncRNAs were significantly associated with lymph node metastasis. Among them, we conducted a meta-analysis to further analyze the relationship between CCAT1 expression and clinical features. Our results indicated that CCAT1 expression was significantly correlated with tumor stage and lymph node metastasis in CCA. The above-mentioned results were also reported in other tumors, such as breast cancer[@b39-ott-12-1905] and esophageal squamous cell carcinoma.[@b40-ott-12-1905] However, Arunkumar et al found that CCAT1 was not obviously associated with tumor stage and the lymph node metastasis in oral squamous cell carcinomas (*P*\>0.05).[@b41-ott-12-1905] Similarly, another meta-analysis was also performed to analyze the relationship between CCAT2 expression and clinical features. As a result, CCAT2 indicated that upregulation of CCAT2 was obviously associated with tumor stage in CCA.

In our analysis of the prognostic value of lncRNAs, all included studies demonstrated that the overexpression of lncRNAs was associated with a poor prognosis. Among these lncRNAs, the CCAT family was investigated in more than one study. After analysis, the results showed that high expression of CCAT family members predicted shorter OS, especially CCAT2. Our result is consistent with the previous findings, while more research is needed to verify this conclusion due to the small sample size of this study.[@b42-ott-12-1905],[@b43-ott-12-1905]

This study was not without limitations. Firstly, the number of studies included was small. Most lncRNAs appeared only once within the incorporated studies and few lncRNAs appeared in more than two different studies, which influenced heterogeneity. Secondly, due to the lack of survival data, we extracted HR and 95% CI values from a Kaplan--Meier curve according to Tierney et al methodology, which might also cause potential heterogeneity. Thirdly, because all the included studies were from China, these results might not be applicable to other ethnicities, such as Caucasians. Next, different cutoff values and follow-up end points were used among the included studies, leading to potential heterogeneity. Finally, studies with positive results were more likely to be published, which may result in an exaggeration of the clinical values of lncRNAs in CAA. In spite of these limitations, our study effectively confirmed the important role of various lncRNA expressions in CAA and encouraged researchers to explore the underlying mechanisms in the future.

So far, there are no reports about the application of lncRNA as a biomarker in clinical practice. However, some lncRNAs have been shown to be more sensitive and specific than existing markers.[@b44-ott-12-1905],[@b45-ott-12-1905] So we believe that some lncRNAs will be identified for use in the clinic as biomarkers in the future.

Conclusion
==========

Taken together, our results show that some specific lncRNAs are significantly associated with clinical value in CAA patients. Among them, upregulation of CCAT1 is significantly associated with tumor stage (I + II vs III + IV) and lymph node metastasis for CCA. Overexpression of CCAT2 is obviously related with tumor stage. Additionally, high expression of CCAT family members predicted shorter OS, especially with regards to CCAT2. However, further large-scale and high-quality studies should be included to confirm our findings and to verify the clinical value of lncRNAs in CCA.
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###### 

The association between lncRNAs and clinicopathological features

  Study                                 Region   lncRNA      Simple size (n)   Detection method   Expression   Age     Gender (*P*-value)   Tumor size (cm)   Histological grade (I--IV)   Tumor stage   Vascular invasion   Lymph node metastasis   Distant metastasis   CA199   AFP     HBV
  ------------------------------------- -------- ----------- ----------------- ------------------ ------------ ------- -------------------- ----------------- ---------------------------- ------------- ------------------- ----------------------- -------------------- ------- ------- -------
  Wang et al, 2016[@b20-ott-12-1905]    China    H19         72                RT-qPCR            Up           0.954   0.538                0.001 (5)         0.091                        0.062         0.144               0.005                   0.092                0.924   0.031   NA
  Ma et al, 2015[@b22-ott-12-1905]      China    CPS1-IT1    31                RT-qPCR            Up           0.862   0.693                0.677 (NA)        NA                           NA            0.642               0.045                   NA                   0.044   NA      NA
  Lv et al, 2017[@b19-ott-12-1905]      China    EMP1-008    72                RT-qPCR            Down         0.89    0.412                0.314 (5)         NA                           NA            NA                  NA                      0.012                0.819   0.603   0.914
  ATF3-008                              Down     0.388       0.431             0.304 (5)          NA           NA      NA                   NA                0.001                        0.321         0.482               0.484                                                        
  RCOR3-013                             Up       0.917       0.359             0.379 (5)          NA           NA      NA                   NA                0.03                         0.923         0.319               0.926                                                        
  TMEM63A-005                           Up       0.941       0.826             0.271 (5)          NA           NA      NA                   NA                0.955                        0.141         0.094               0.807                                                        
  Xu et al, 2017[@b8-ott-12-1905]       China    CCAT1       91                RT-qPCR            Up           0.413   0.875                NA                0.636                        0.005         NA                  0.01                    NA                   0.490   NA      0.909
  Zhang et al, 2017[@b24-ott-12-1905]   China    CCAT1       120               RT-qPCR            Up           0.938   0.407                NA                0.612                        \<0.01        NA                  \<0.01                  NA                   NA      NA      NA
  Xu et al, 2017[@b25-ott-12-1905]      China    PANDAR      67                RT-qPCR            Up           0.307   0.457                NA                0.014                        0.034         0.794               0.004                   NA                   0.221   NA      0.788
  Lu et al, 2017[@b11-ott-12-1905]      China    AFAP1-AS1   56                RT-qPCR            Up           0.768   1.000                0.031 (5)         0.003                        0.013         0.011               0.540                   0.177                NA      NA      1.000
  Zhang et al, 2017[@b24-ott-12-1905]   China    Linc01296   57                RT-qPCR            Up           0.553   0.789                0.003 (3)         NA                           0.024         NA                  0.031                   NA                   NA      NA      NA
  Tan et al, 2017[@b12-ott-12-1905]     China    MALAT1      62                RT-qPCR            Up           0.602   0.799                0.042 (3)         NA                           0.037         NA                  0.037                   NA                   NA      NA      NA
  Xu et al, 2017[@b25-ott-12-1905]      China    UCA1        68                RT-qPCR            Up           0.621   0.807                NA                0.307                        0.004         NA                  0.027                   NA                   NA      NA      NA
  Li et al, 2017[@b11-ott-12-1905]      China    Sox2ot      58                RT-qPCR            Up           0.301   0.571                NA                0.849                        0.007         0.203               0.031                   NA                   0.067   NA      0.813
  Xu et al, 2017[@b25-ott-12-1905]      China    H19         56                RT-qPCR            Up           0.282   0.596                0.029 (3)         0.783                        0.015         0.245               0.105                   NA                   0.173   NA      0.418
  Xia et al, 2018[@b27-ott-12-1905]     China    CRNDE       118               RT-qPCR            Up           0.276   0.306                0.001 (5)         0.046                        0.050         0.742               NA                      0.114                0.172   0.374   NA
  Bai et al, 2018[@b28-ott-12-1905]     China    CCAT2       106               RT-qPCR            Up           0.204   0.620                0.326 (5)         0.040                        \<0.001       \<0.001             NA                      NA                   0.327   NA      0.919
  Xu et al, 2018[@b29-ott-12-1905]      China    CCAT2       60                RT-qPCR            Up           0.435   0.796                0.228 (3)         0.414                        0.010         NA                  0.019                   NA                   NA      NA      NA
  Xu et al, 2018[@b29-ott-12-1905]      China    HOTAIR      70                RT-qPCR            Up           0.624   0.544                0.028 (3)         0.609                        0.021         0.468               0.805                   NA                   0.609   NA      0.789

**Abbreviations:** RT-qPCR, real-time quantitative PCR; CA199, carbohydrate antigen 199; AFP, alpha-fetoprotein; HBV, hepatitis B virus; NA, not available.

###### 

Summary of lncRNAs used as diagnostic biomarkers of cholangiocarcinoma

  Study                              Region   lncRNA              Expression   SE (%)   SP (%)   AUC     Sample size   Detected sample   QUADAS        
  ---------------------------------- -------- ------------------- ------------ -------- -------- ------- ------------- ----------------- ------------- ---
  Xu et al, 2017[@b8-ott-12-1905]    China    CCTA1               Up           81.80    74.50    0.831   91            91                Tissue        7
  Ge et al, 2017[@b31-ott-12-1905]   China    ENST00000517758.1   Up           --       --       0.613   35            56                Bile sample   5
  ENST00000588480.1                  Up       62.90               73.20        0.680                                                                   

**Abbreviations:** SE, sensitivity; SP, specificity; AUC, area under curve; QUADAS, Quality Assessment of Diagnostic Accuracy Studies.

###### 

Summary of lncRNAs used as prognostic biomarkers of cholangiocarcinoma

  Study                                 Region   lncRNA              Expression   Detected sample   Test method   Cutoff       Sample size   Survival analysis   HR availability   Follow-up month   NOS   
  ------------------------------------- -------- ------------------- ------------ ----------------- ------------- ------------ ------------- ------------------- ----------------- ----------------- ----- ---
  Ma et al, 2015[@b22-ott-12-1905]      China    CPS1-IT1            Up           Tissue            RT-qPCR       FC\>4        22            9                   DFS               Indirectly        40    5
  Tan et al, 2017[@b12-ott-12-1905]     China    MALAT1              Up           Tissue            RT-qPCR       Median       31            31                  OS                Indirectly        30    6
  Xu et al, 2017[@b8-ott-12-1905]       China    CCAT1               Up           Tissue            RT-qPCR       Median       47            44                  OS                Indirectly        50    5
  Zeng et al, 2017[@b32-ott-12-1905]    China    TUG1                Up           Tissue            RT-qPCR       NA           51            51                  OS                Directly          100   6
  DFS                                                                                                                                                                                                      
  Xu et al, 2017[@b8-ott-12-1905]       China    PANDAR              Up           Tissue            RT-qPCR       NA           40            27                  OS                Directly          60    5
  DFS                                                                                                                                                                                                      
  Lu et al, 2017[@b11-ott-12-1905]      China    AFAP1-AS1           Up           Tissue            RT-qPCR       Median       28            28                  OS                Indirectly        80    5
  Zhang et al, 2017[@b24-ott-12-1905]   China    LINC01296           Up           Tissue            RT-qPCR       Mean         35            22                  OS                Indirectly        60    5
  Xu et al, 2017[@b8-ott-12-1905]       China    UCA1                Up           Tissue            RT-qPCR       NA           38            30                  OS                Directly          60    7
  Li et al, 2015[@b36-ott-12-1905]      China    Sox2ot              Up           Tissue            RT-qPCR       Median       30            28                  OS                Directly          60    6
  Xia et al, 2017[@b27-ott-12-1905]     China    CRNDE               Up           Tissue            RT-qPCR       Mean         51            67                  OS                Directly          60    6
  Xu et al, 2018[@b24-ott-12-1905]      China    H19                 Up           Tissue            RT-qPCR       NA           31            25                  OS                Indirectly        60    5
  Ge et al, 2017[@b31-ott-12-1905]      China    ENST00000588480.1   Up           Tissue            RT-qPCR       Median       18            17                  OS                Indirectly        70    6
  ENST00000517758.1                                                                                                                                                                                        
  Xu et al, 2018[@b29-ott-12-1905]      China    SPRY4-IT1           Up           Tissue            RT-qPCR       Mean         41            29                  PFS               Indirectly        60    5
  OS                                                                                                                                                                                                       
  Bai et al, 2018[@b28-ott-12-1905]     China    CCAT2               Up           Tissue            RT-qPCR       Score =4.4   45            61                  OS                Directly          72    7
  PFS                                                                                                                                                                                                      
  Xu et al, 2018[@b29-ott-12-1905]      China    CCAT2               Up           Tissue            RT-qPCR       Mean         34            26                  OS                Directly          60    7
  Qin et al, 2018[@b30-ott-12-1905]     China    HOTAIR              Up           Tissue            RT-qPCR       NA           43            27                  OS                Directly          60    6

**Abbreviations:** DFS, disease-free survival; OS, overall survival; PFS, progression-free survival; RT-qPCR, real-time quantitative polymerase chain reaction; NOS; Newcastle-Ottawa Scale; FC, fold-change; NA, not available.
